EUVIMEDEUVIMED entdecken
Crossref

Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety

Rebecca De Lorenzo, Mario G Mazza, Clara Sciorati, Roberto Leone, Francesco Scavello, Mariagrazia Palladini, Aurora Merolla, Fabio Ciceri, Barbara Bottazzi, Cecilia Garlanda, Francesco Benedetti, Patrizia Rovere-Querini und 1 weitere

CNS Drugs · 2024

DOI: 10.1007/s40263-024-01081-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Drugs, 2024. Verfasst von Rebecca De Lorenzo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Anxiety, Biomarkers, C-Reactive Protein, COVID-19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 76 Literaturangaben. Gefördert von: Ministero della Salute, NextGeneration EU-MUR PNRR, Philanthropic donation by Dolce & Gabbana fashion.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Clinical manifestations of coronavirus disease 2019 (COVID-19) often persist after acute disease resolution. Underlying molecular mechanisms are unclear. The objective of this original article was to longitudinally measure plasma levels of markers of the innate immune response to investigate whether they associate with and predict post-COVID symptomatology. METHODS: Adult patients with previous severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection during the first pandemic wave who underwent the 6-month multidisciplinary follow-up were included. Plasma levels of pentraxin 3 (PTX3), the complement components C3a and C5a, and chitinase-3 like-protein-1 (CHI3L1) were measured at hospital admission during acute disease (baseline) and at 1 and 6 months after hospital discharge. Associations with post-COVID-19 sequelae at 6 months were investigated using descriptive statistic and multiple regression models. RESULTS: Ninety-four COVID-19 patients were included. Baseline PTX3, C5a, C3a, and CHI3L1 did not predict post-COVID-19 sequelae. The extent of the reduction of PTX3 over time (delta PTX3) was associated with lower depressive and anxiety symptoms at 6 months (both p < 0.05). When entering sex, age, need for intensive care unit or non-invasive ventilation during hospital stay, psychiatric history, and baseline PTX3 as nuisance covariates into a generalized linear model (GLM), the difference between baseline and 6-month PTX3 levels (delta PTX3) significantly predicted depression (χ2 = 4.66, p = 0.031) and anxiety (χ2 = 4.68, p = 0.031) at 6 months. No differences in PTX3 levels or PTX3 delta were found in patients with or without persistent or new-onset other COVID-19 symptoms or signs at 6 months. Plasma levels of C3a, C5a, and CHI3L1 did not correlate with PTX3 levels at either time point and failed to associate with residual or de novo respiratory or systemic clinical manifestations of the disease at 6 months. CONCLUSIONS: A lower reduction of plasma PTX3 after acute COVID-19 associates with the presence of depression and anxiety, suggesting an involvement of inflammation in post-COVID-19 psychopathology and a potential role of PTX3 as a biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnxietyBiomarkersC-Reactive ProteinCOVID-19Post-Acute COVID-19 SyndromeSerum Amyloid P-ComponentAdultAgedFemaleHumansMaleMiddle AgedDepressionFollow-Up StudiesLongitudinal StudiesPentraxins

Substanzen

BiomarkersC-Reactive ProteinSerum Amyloid P-ComponentPentraxins

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Unit of Innate Immunity and Tissue Remodeling, Department of Internal Medicine, Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy. mazza.mariogennaro@hsr.it.
  • IRCCS Humanitas Research Hospital, Rozzano, Italy.
  • Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Scientific Institute Ospedale San Raffaele, San Raffaele Turro, Via Stamira d'Ancona 20, 20127, Milan, Italy.
  • Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele, Milan, Italy.

Förderung

  • Ministero della Salute
  • NextGeneration EU-MUR PNRR
  • Philanthropic donation by Dolce & Gabbana fashion

Zitieren

APA

De Lorenzo, R., Mazza, M. G., Sciorati, C., Leone, R., Scavello, F., Palladini, M., Merolla, A., Ciceri, F., Bottazzi, B., Garlanda, C., Benedetti, F., Rovere-Querini, P., & Manfredi, A. A. (2024). Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety. CNS Drugs. https://doi.org/10.1007/s40263-024-01081-4

Vancouver

De Lorenzo R, Mazza MG, Sciorati C, Leone R, Scavello F, Palladini M, et al. Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety. CNS Drugs. 2024. doi:10.1007/s40263-024-01081-4

BibTeX
@article{DeLorenzo2024,
  author = {De Lorenzo, Rebecca and Mazza, Mario G and Sciorati, Clara and Leone, Roberto and Scavello, Francesco and Palladini, Mariagrazia and Merolla, Aurora and Ciceri, Fabio and Bottazzi, Barbara and Garlanda, Cecilia and Benedetti, Francesco and Rovere-Querini, Patrizia and Manfredi, Angelo A},
  title = {Post-COVID Trajectory of Pentraxin 3 Plasma Levels Over 6 Months and Their Association with the Risk of Developing Post-Acute Depression and Anxiety},
  journal = {CNS Drugs},
  year = {2024},
  doi = {10.1007/s40263-024-01081-4}
}
Kostenlos starten →